Geron Corporation (NASDAQ:GERN), a medical sector company, announced its results for the last quarter on 03/01/2017. The company traded a total of 2.65 Million shares in the last trading session, representing a 2.64% decrease. Analysts have set the company’s price target at 5 against the 1-year price target of 4.15. In this quarter, investors had set a price target of -0.05.
Going by performance, Geron Corporation’s shares have the ability to hit a per share high of -0.05 and a per share low of -0.05 for the current quarter. These earnings projections are a consensus of three analysts. According to the analysts, the average EPS that the company can deliver is -0.05 per share. The actual EPS reported by the company for the same period in the previous year was -0.06per share.
Analysts recommended that Geron could deliver EPS of -0.06 per share in the quarter ending 11/03/2016. The company however announced an actual -0.02 per share indicating a variation of 0.04% between Actual and Estimated EPS. This led to surprise factor of 66.7%.
In the previous quarter, analysts estimated $-0.06 per share and the company announced an Actual EPS of $-0.05 per share yielding a difference of 0.01% and a surprise of 16.7%.
The three analysts covering the 12-months price prediction for Geron Corp have an average of 5.00 with the upper limit being 5.00 and the lower limit being 2.50. The average estimate reflects a +126.24% raise from 2.21 which was reported in the last quarter. The company recorded a sales growth of -15.8%.
Geron Corporation reached a 52-week high price target of .35 on Apr 25, 2016 and a 52-week low of 1.81 on Nov 3, 2016.
The company’s stock has a share cap of 356.5 Million. This year’s growth rate fell by -15.8% and next year’s growth rate set at 104.5% with a 5% long term growth projection.
Geron Corporation is a research company engaged in the development of techniques applicable in the health services industry. The company’s research is currently sectioned in three different sectors. i.e. telomeres and telomerase, pluripotent stem cells and nuclear transfer.
